Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Cardiotoxicity associated with MCL-1 inhibition for R/R hematologic malignancies

Pinkal Desai • 5 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia AZD5991 Venetoclax

Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the use of the MCL-1 inhibitor AZD5991 for relapsed or refractory (R/R) hematologic malignancies. Despite AZD5991 being discontinued due to cardiotoxicity, Dr Desai explains how it should encourage future studies to incorporate cardiotoxicity measures for more optimal development. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Pinkal Desai

Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallman et al. • 20 Sep 2026
Real-world data support olutasidenib after venetoclax in IDH1-mutated AML
2:33
Real-world data support olutasidenib after venetoclax in IDH1-mutated AML
Pinkal Desai • 12 Jun 2026
Could luspatercept modify disease in lower-risk myelodysplastic syndromes?
2:57
Could luspatercept modify disease in lower-risk myelodysplastic syndromes?
Pinkal Desai • 13 Jun 2026
Predicting and preventing therapy-related myeloid neoplasms
3:30
Predicting and preventing therapy-related myeloid neoplasms
Pinkal Desai • 7 Dec 2025

Related Videos

Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals